Reference number(s)
1777-H

SPECIALTY QUANTITY LIMIT PROGRAM

Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors

I. PROGRAM DESCRIPTION

The recommended dosing parameters for all FDA-approved indications that fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Repatha 140 mg syringe or SureClick autoinjector	2 per 28 days	Established cardiovascular disease or primary hyperlipidemia: 140 mg every 2 weeks or 420 mg once monthly Homozygous familial hypercholesterolemia: 420 mg once monthly
Repatha 420 mg Pushtronex system	1 per 28 days	
Praluent 75 mg pen	2 per 28 days	Initial dose: 75 mg every two weeks. If the LDL-C response is inadequate, dosage may be adjusted to the maximum 150 mg every 2 weeks Alternative starting dose for less frequent dosing: 300 mg every 4 weeks. If LDL-C response is inadequate, dosage may be adjusted to 150 mg every 2 weeks
Praluent 150 mg syringe/pen	2 per 28 days	

III. REFERENCES

1. Repatha [package insert]. Thousand Oaks, CA: Amgen, Inc.; December 2017.
2. Praluent [package insert]. Bridgewater, NJ: Sanofi-aventis U.S., LLC; September 2017.

CVS caremark™